Based on this finding, joint guidelines recently published by the American Society of Clinical Oncology (ASCO) and Ontario Health (OH) stated that where available, osimertinib should be the optimal first-line treatment for NSCLC patients with sensitising EGFR mutations [35]. Here, EGFR is linked to non-small cell lung carcinoma.